Histamine Receptor Antagonists and Lipid Stability in Total Nutrient Admixtures

Abstract

Drug stability and compatibility studies should be performed for all medications added to total nutrient admixtures (TNAs) before administration to patients. The stability of TNA components will vary depending on product selection and final concentrations. This variability prohibits generalizing published study results generically to TNAs containing untested products or combinations. Histamine receptor antagonists (H₂RAS) are commonly administered by continuous infusion via nutrient solutions. When the delivery vehicle is a TNA, comparative stability and compatibility studies performed under similar test conditions are lacking. The stability of marketed parenteral H₂RAs and of the investigational H₂RA, nizatidine was analyzed in TNA solutions containing either Liposyn II or Intralipid at differing concentrations. All H₂RAS remained at more than 90% of initial concentration at 24 hours. After 48 hours, only ranitidine concentrations fell to less than 90% in all study solutions. Each TNA containing an H₂RA was within pH stability ranges for lipid products, and no change in particle size was detected during the 48-hour period. This is the first report determining H₂RA compatibility and stability in TNA solutions with both 3% and 5% Intralipid and Liposyn II and using similar methodology for all standard H₂RA concentrations. Results suggest that these drugs are stable for 24 hours in TNAs containing either lipid product. Beyond this time, administration of ranitidine may be unreliable because of poor stability under the conditions tested. (Journal of Parenteral and Enteral Nutrition 18:308–312, 1994)

Get full access to this article

View all access options for this article.

References

1. Driscoll DF , Baptista RJ , Mitrano FP, et al : Parenteral nutrient admixtures as drug vehicles: Theory and practice in the critical care setting. DICP-Ann Pharmacother 25:276–282, 1991.

2. Trissel LA : Drug stability and compatibility issues in drug delivery. IN Handbook on Injectable Drugs, 7th ed, Trissel LA (ed). American Society of Hospital Pharmacists's Special Practice Division, Bethesda, MD, 1992.

3. Driscoll DF , Lowell JA , Nompleggi D, et al : Continuous versus intermittent cimetidine in acutely ill hospitalized patients: The role of the TPN admixture as a drug vehicle. Nutrition 6:383–388, 1990.

4. Ostro MJ , Russell JA , Soldin SJ, et al : Control of gastric pH with cimetidine: Bolus versus primed infusions. Gastroenterology 89:532–537, 1985.

5. Ballesteros MA , Hogan D , Koss MA, et al : Bolus or intravenous infusion of ranitidine: Effects on gastric pH and acid secretion. Ann Intern Med 112:334–339, 1990.

6. Hatton J , Holstad SG , Rosenbloom AD, et al : Stability of nizatidine in total nutrient admixtures. Am J Hosp Pharm 48:1507–1510, 1991.

7. Cano SM , Montoro JB , Pastor C, et al : Stability of ranitidine hydrochloride in total nutrient admixtures. Am J Hosp Pharm 45:1100–1102, 1988.

8. Baptista RJ , Palumbo JD , Tahan SR, et al : Stability of cimetidine hydrochloride in a total nutrient admixture. Am J Hosp Pharm 42:2208–2210, 1985.

9. Tsallas G , Allen LC : Stability of cimetidine hydrochloride in parenteral nutrition solutions. Am J Hosp Pharm 39:484–485, 1982.

10.

10. Bullock L , Parks RB , Lampasona V, et al : Stability of ranitidine hydrochloride and amino acids in parenteral nutrient solutions. Am J Hosp Pharm 42:2683–2687, 1985.

11.

11. Walker SE , Bayliff CD : Stability of ranitidine hydrochloride in total parenteral nutrient solution. Am J Hosp Pharm 42:590–592, 1985.

12.

12. Bullock L , Fitzgerald JF , Glick MR, et al : Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions. Am J Hosp Pharm 46:2321–2325, 1989.

13.

13. Shea BF , Souney PF : Stability of famotidine in a 3 in 1 total nutrient admixture. DICP-Ann Pharmacother 24:232–235, 1990.

14.

14. Cano SM , Montoro JB , Pastor C, et al : Stability of cimetidine in total parenteral nutrition. J Clin Nutr Gastroenterol 2:40–43, 1987.

15.

15. Montoro SB , Pou L , Salvador P, et al : Stability of famotidine 20 mg and 40 mg/L in total nutrient admixtures. Am J Hosp Pharm 46:2329–2332, 1989.

16.

16. Williams MF , Hak LJ , Dukes G : In vitro evaluation of the stability of ranitidine hydrochloride in total parenteral nutrient mixtures. Am J Hosp Pharm 47:1574–1579, 1990.

17.

17. Mehta RC , Head LF , Hazrati AM, et al : Fat emulsion particle-size distribution in total nutrient admixtures. Am J Hosp Pharm 49:2749–2755, 1992.

18.

18. Geyer RP , Watkin DM , Mathews LW, et al : Parenteral nutrition. XI. Studies with stable and unstable fat emulsions administered intravenously. Proc Soc Exp Biol Med 77:872–876, 1951.

19.

19. LeVeen HH , Giordano P , Spletzer J : The mechanism of removal of intravenously injected fat Its relationship to toxicity. Arch Surg 83:311–321, 1961.

20.

20. Atik M , Marrero R , Isla F, et al : Hemodynamic changes following infusion of intravenous fat emulsions. Am Clin Nutr 16:68–74, 1965.

21.

21. Fujita T , Sumaya T , Yokoyama K : Fluorocarbon emulsion as a candidate for artificial blood: Correlation between particle size of emulsion and acute toxicity. Eur Surg Res 3:436–453, 1971.

22.

22. Burnham WR , Hansrani PK , Knott CE, et al : Stability of a fat emulsion based intravenous feeding mixture. Int J Pharm (Amst) 13:9–22, 1983.

23.

23. Schroeder HG , Simmons GH , DeLuca PP : Distribution of radiolabeled subvisible microspheres after intravenous administration to beagle dogs. J Pharm Sci 67:504–507, 1978.

24.

24. Kanke M , Simmons GH , DeLuca PP, et al : Clearance of 141 Ce-labeled microspheres from blood and distribution in specific organs following intravenous and intraarterial administration in beagle dogs. J Pharm Sci 69:755–762, 1980.

25.

25. Slack JD , Kanke M , DeLuca PP, et al : Acute hemodynamic effects and blood pool kinetics of polystyrene microspheres following intravenous administration. J Pharm Sci 70:660–664, 1981.

26.

26. Kanke M , Geissler R , DeLuca PP, et al : Interaction of microspheres with blood constituents. III. Macrophage phagocytosis of various types of polymeric drug carriers. J Pharm Sci 42:157–165, 1988.